Biovie INC Form 4 insider transactions

BIOVIE Inc.'s Chief Medical Officer, Joseph M Palumbo, was granted 132,000 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc.'s Chief Financial Officer, Joanne Wendy Kim, acquired 110,100 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc. Director Sigmund Rogich was granted 211,100 stock options with an exercise price of $1.31, vesting over various periods.

BIOVIE Inc.'s President and CEO, Cuong V. Do, was granted 665,300 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc. Director Michael Edward Sherman reported the acquisition of 421,100 stock options with an exercise price of $1.31, vesting over several years.

Kameel D. Farag, a Director at BIOVIE INC., was granted 57,500 stock options with an exercise price of $1.31, vesting over time.

BIOVIE Director Amy Suzon Chappell was granted 57,500 stock options with an exercise price of $1.31, vesting over time.

BIOVIE Inc. Director James Paul Lang was granted 420,500 stock options with an exercise price of $1.31, vesting over several years.

BIOVIE Inc.'s President & CEO, Cuong V Do, acquired 5,000 shares of common stock and 5,000 warrants at a combined price of $2.00 per unit in a public offering closing on August 11, 2025.

Director Sigmund Rogich reports acquisition of BioVie Inc. stock and stock options via restricted stock units and option grants.

Director Richard J. Berman reported the acquisition of common stock and stock options in BioVie Inc.

BioVie Inc. director Michael Sherman has acquired stock options in two separate transactions, according to a recent SEC filing.

Director James Paul Lang reports acquisition of stock options in BioVie Inc.

Director Robert Hariri reports acquisition of stock options in BioVie Inc.

Joseph M. Palumbo, Chief Medical Officer of BioVie Inc., reports the acquisition of stock options.

Chief Financial Officer of BioVie Inc., Joanne Wendy Kim, reports the acquisition of stock options.

BioVie Inc.'s CEO, Cuong V Do, acquired 104,502 stock options on December 20, 2024, which vest over three years.

Joseph M. Palumbo, Chief Medical Officer of BioVie Inc., reports acquisition and disposal of common stock and stock options.

Joanne Wendy Kim, CFO of BioVie Inc., reports acquisition and disposal of common stock and stock options.

BioVie Inc.'s CEO, Cuong V Do, reports acquisition and disposal of common stock and stock options, including a grant of restricted stock units.

BioVie Inc.'s CEO, Cuong V Do, reports the acquisition of 10,000 shares of common stock and 5,000 warrants through a recent public offering.